BioHarvest Sciences Reports Q3 2026 Financial Results Amid Strategic Shift to Fragrance Development
BioHarvest Sciences (BHST) reported third-quarter revenue of $7.9 million, a decrease from $9.1 million in the prior year. The decline is attributed to a deliberate strategic pivot toward selective customer acquisition and changes in contract revenue timing. Gross profit margins also compressed to 54% from 61%, as the revenue mix shifted toward lower-margin products. The company is heavily prioritizing its rare fragrance development program, which has increased R&D spending to $1.8 million. While this transition has widened the adjusted EBITDA loss to $2 million and resulted in a net loss of $3.3 million, management anticipates significant long-term upside from the fragrance segment, projecting potential revenue of $20 million to $30 million across 2027 and 2028. Despite these growth prospects, BioHarvest faces significant financial headwinds. Management issued a warning regarding 'material uncertainty' about the company's ability to continue as a going concern due to ongoing operating losses and the necessity for future capital injections.
Topics: financial guidance gross profit margin net loss R&D expenses revenue decline